Introduction: Sepsis can be identified and classified using biomarkers, which can aid in understanding critical illness. Vasoactive hormone adrenomedullin has been shown to have prognostic and maybe therapeutic value in sepsis. This study's objective is to assess the prognostic value of the serum level of admission bio-ADM in critically ill patients. Patients & Methods: In this observational prospective study, patients who were admitted to Minia University Hospitals' medical critical care unit (ICU) between December 2020 and November 2021 underwent a complete blood count, CRP as well as renal and liver function tests and blood culture. All patients had their bio-adrenomedullin levels evaluated by ELISA at the time of admission. Results: The work included 114 patients who were subdivided into 3 groups: non-septic group including SIRS patients with negative blood culture (n=44), mild sepsis group including patients with SOFA score ≥2 without organ dysfunction (n=26), and severe sepsis group including sepsis patients with organ dysfunction or refractory hypotension (n=44). There was a significant difference in distribution of the quartiles of bio-ADM between survivor and non-survivors.

Conclusion: measuring bio ADM levels in the blood enables the early diagnosis and warning of sepsis.